caa a22 4500 465789684 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171841 doi (NATIONALLICENCE)springer-10.1007/BF00171841 Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer [Elektronische Daten] [Jin Lee, Herman Libshitz, William Murphy, Diane Jeffries, Waun Hong] Summary: Thirty-one patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with intravenous 10-EdAM on a weekly basis. The starting dose was 80 mg/m2, with subsequent doses adjusted depending on evidence of toxicity. There were 20 men and 11 women with a median age of 58 years (range, 33-75). Response was evaluated in 30 patients, 5 with evaluable but not measurable tumors and 25 with measurable indicator lesions. There were no complete remissions; 3 patients achieved partial remission. Nine patients had a minor response, 6 showed no change, and 12 had progressive disease. Median survival for all 31 patients was 43 weeks (range, 12-65+). During the first 3-week period, the 10-EdAM dose was reduced or withheld in 19 patients (because of stomatitis in 12, SGPT elevation in 3, skin rash in 2, and granulocytopenia in 2), escalated in 11 patients, and unchanged in 1 patient. A mean of 34-88 mg/m2of 10-EdAM (median, 50) was given per week during the first 5-week period. Myelotoxicity was infrequent and there was no significant nephrotoxicity. Considering the modest side effects of this treatment and the conservative dose-modification schedule which mandated substantial dose reductions, we conclude that 10-EdAM is a promising antitumor agent for NSCLC. Kluwer Academic Publishers, 1990 non-small cell lung cancer nationallicence chemotherapy nationallicence 10-ethyl-10-deaza-aminopterin nationallicence 10-EdAM nationallicence Lee Jin Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut Libshitz Herman Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut Murphy William Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut Jeffries Diane Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut Hong Waun Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 299-304 0167-6997 8:3<299 1990 8 10637 https://doi.org/10.1007/BF00171841 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171841 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lee Jin Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Libshitz Herman Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Murphy William Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Jeffries Diane Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut NATIONALLICENCE 700 1- Hong Waun Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, Texas, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 299-304 0167-6997 8:3<299 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer